Core Viewpoint - The stock of Jinyu Biological Technology Co., Ltd. has shown significant growth this year, with an 81.11% increase in share price, indicating strong market performance and investor interest [1][2]. Company Overview - Jinyu Biological Technology Co., Ltd. is located in Hohhot, Inner Mongolia, and was established on March 13, 1993, with its stock listed on January 15, 1999. The company primarily engages in the research, production, and sales of veterinary biological products [1]. - The main revenue composition includes 94.42% from biopharmaceuticals, 3.18% from other income, and 2.40% from supplementary sources [1]. Financial Performance - For the period from January to September 2025, the company achieved an operating income of 1.042 billion yuan, representing a year-on-year growth of 7.38%. However, the net profit attributable to shareholders decreased by 4.85% to 161 million yuan [2]. - The company has distributed a total of 2.219 billion yuan in dividends since its A-share listing, with 189 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 10.70% to 49,000, while the average circulating shares per person increased by 11.12% to 22,673 shares [2]. - Notable institutional shareholders include Guotai Zhongxin Livestock Breeding ETF, which holds 25.0398 million shares, and Hong Kong Central Clearing Limited, holding 21.1968 million shares, both showing increases in their holdings [3].

Core Viewpoint - The animal health sector experienced a slight decline of 0.31% on November 19, with Xianfeng Holdings leading the losses, while the Shanghai Composite Index rose by 0.18% to close at 3946.74 [1]. Group 1: Market Performance - The animal health sector's individual stock performance varied, with notable gainers including Qudongli (up 3.98% to 10.71) and ST Lvkang (up 3.80% to 46.40) [1]. - Conversely, several stocks faced declines, such as Jinhai Biological (down 0.96% to 6.19) and Shunlian Biological (down 1.08% to 10.12) [1][2]. Group 2: Trading Volume and Capital Flow - The total trading volume for the animal health sector was significant, with Qudongli achieving a volume of 34,000 hands and a transaction value of approximately 35.9 million yuan [1]. - The sector saw a net outflow of 49.13 million yuan from institutional investors, while retail investors contributed a net inflow of 548.09 million yuan [2]. Group 3: Individual Stock Capital Flow - Among individual stocks, Shengong Holdings experienced a net outflow of 31.56 million yuan from retail investors, while Biotech Holdings saw a net inflow of 555.72 million yuan from retail investors [3]. - The stock with the highest net inflow from retail investors was Biotech Holdings, with 555.72 million yuan, while the largest net outflow was from Yongshun Biological, totaling 408.61 million yuan [3].

Core Insights - The swine industry is experiencing significant losses, with the average selling price of live pigs dropping to 11.56 yuan/kg, leading to a loss of 71.95 yuan per head for self-bred pigs [1] - Analysts suggest that the current oversupply and weak demand may result in a "non-peak" season for pork prices in Q4, indicating potential investment opportunities in the sector [1] - The industry is expected to undergo capacity reduction, which may lead to an upward adjustment of pork price levels by 2026, benefiting low-cost producers [1] Group 1: Market Performance - As of November 18, 2025, the China Livestock Breeding Index (930707) showed mixed performance among its constituent stocks, with Muyuan Foods (002714) leading with a 0.43% increase [1] - The Livestock ETF (516760) was quoted at 0.7 yuan [1] - The top ten weighted stocks in the index accounted for 65.58% of the total index weight, indicating a concentration in a few key players [2] Group 2: Stock Performance - The stock performance of key companies includes: - Muyuan Foods (002714): +0.43%, weight 11.37% - Haida Group (002311): +0.34%, weight 9.52% - Biological Shares (600201): +0.25%, weight 3.91% - Other notable declines include New Hope (000876): -1.01% and Tian康 Biological (002100): -1.96% [4]

Core Points - The chairman of Baolingbao Biotech Co., Ltd., Mr. Dai Jue, has resigned due to personal reasons, effective immediately upon submission of his resignation report [1][2] - Mr. Dai Jue will continue to serve as a director for the company's wholly-owned subsidiaries, BLB International Development (Singapore) PTE. LTD. and BLB Bio-Tech USA INC [1] - The resignation will not affect the minimum number of board members or the normal operation of the board and the company [2] Company Information - Mr. Dai Jue holds 29,508,653 shares of the company through Beijing Yongyu Investment Management Co., Ltd., representing 7.75% of the total share capital, and is one of the actual controllers of the company [2] - The board expressed gratitude for Mr. Dai Jue's contributions to the company's strategic development and stable operations during his tenure [2]

Core Viewpoint - The company, Jinyu Biotechnology Co., Ltd., is set to hold a performance briefing for the third quarter of 2025 on November 26, 2025, to discuss its operational results and financial status with investors [2][3]. Group 1: Meeting Details - The performance briefing will take place on November 26, 2025, from 15:00 to 17:00 [5]. - The location for the meeting is the Shanghai Stock Exchange Roadshow Center, accessible via the website http://roadshow.sseinfo.com/ [5]. - The meeting will be conducted through video live streaming and online interaction [3][5]. Group 2: Investor Participation - Investors can submit questions for the briefing from November 19, 2025, to November 25, 2025, before 16:00, either through the Roadshow Center website or via the company's email [6]. - The company will address commonly asked questions during the briefing [3][6]. Group 3: Company Representatives - Key representatives attending the meeting include Chairman Zhang Chongyu, CFO Li Kai, and Vice Chairman and President Zhang Jing [4][5].

Core Insights - The animal health sector experienced a decline of 0.24% on November 17, with Dayu Biological leading the drop [1] - The Shanghai Composite Index closed at 3972.03, down 0.46%, while the Shenzhen Component Index closed at 13202.0, down 0.11% [1] Stock Performance - Notable gainers included: - Qudongli (code: 920275) with a closing price of 10.68, up 5.12% [1] - *ST Lvkang (code: 002868) with a closing price of 42.57, up 5.01% [1] - Houfeng Holdings (code: 002141) with a closing price of 3.91, up 2.62% [1] - Major decliners included: - Dayu Biological (code: 920970) with a closing price of 8.70, down 3.87% [2] - Ruipu Biological (code: 300119) with a closing price of 20.61, down 2.92% [2] - Zhongmu Co., Ltd. (code: 600195) with a closing price of 7.94, down 1.98% [2] Capital Flow - The animal health sector saw a net outflow of 10.15 million yuan from institutional investors, while retail investors experienced a net outflow of 20.76 million yuan [2] - Conversely, speculative funds recorded a net inflow of 30.91 million yuan [2] Individual Stock Capital Flow - Notable capital flows included: - Biological Shares (code: 600201) with a net inflow of 12.08 million yuan from institutional investors [3] - Xianfeng Holdings (code: 002141) with a net inflow of 9.50 million yuan from institutional investors [3] - Ruipu Biological (code: 300119) with a net inflow of 1.05 million yuan from speculative funds [3] - Decliners in capital flow included: - *ST Lvkang (code: 002868) with a net outflow of 0.79 million yuan from institutional investors [3] - Hai Li Biological (code: 603718) with a net outflow of 2.82 million yuan from institutional investors [3]

金宇生物技术股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600201 证券简称：生物股份 公告编号：临 2025-061 重要内容提示： 投资者可于 2025 年 11 月 19 日(星期三) 至 11 月 25 日(星期二)16:00 前登 录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 stock@jinyu.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 金宇生物技术股份有限公司（以下简称"公司"）已于 2025 年 10 月 28 日 披露公司《2025 年第三季度报告》，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 26 日(星期三) 下午 15:00-17:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行 交流。 一、 说明会类型 本次投资者说明会以视频结合网络 ...

Core Viewpoint - The animal health sector experienced a slight increase of 0.89% on November 14, with *ST Green Kang leading the gains, while the overall market indices, including the Shanghai Composite Index and Shenzhen Component Index, saw declines of 0.97% and 1.93% respectively [1] Group 1: Market Performance - The closing price of *ST Green Kang was 40.54, reflecting a rise of 5.00% with a trading volume of 204,000 shares and a transaction value of 8.27 million yuan [1] - Other notable performers included Ruipu Biology with a closing price of 21.23, up 1.87%, and Biological Shares at 11.93, up 1.62% [1] - The overall trading volume and transaction values for various companies in the animal health sector were significant, with Biological Shares recording a transaction value of 954 million yuan [1] Group 2: Capital Flow - The animal health sector saw a net outflow of 57.68 million yuan from institutional investors, while retail investors contributed a net inflow of 60.01 million yuan [2] - The capital flow data indicates that *ST Green Kang had a net inflow of 1.42 million yuan from institutional investors, despite a net outflow from retail investors [3] - Other companies like Biological Shares and Ruipu Biology experienced significant net outflows from institutional investors, indicating a shift in investment sentiment [3]

Core Points - The company held its first extraordinary general meeting of shareholders on November 13, 2025, where no resolutions were rejected [2] - The meeting was chaired by the financial director due to the absence of the chairman and general manager [3] - The company approved the proposal to abolish the supervisory board and amend the articles of association, transferring the supervisory powers to the audit committee of the board [9] Meeting Details - The meeting took place at the company's innovation park in Qingdao [2] - The voting method combined on-site and online voting, complying with the Company Law and the company's articles of association [2] - Out of 5 current directors, 3 attended the meeting, while 1 supervisor attended out of 3 [3] Resolutions Passed - The following proposals were approved: - Abolishment of the supervisory board and amendment of the articles of association [4] - Amendments to various governance documents, including the rules for shareholder meetings, board meetings, independent director systems, and management of fundraising [4][5][6] - The proposals requiring special resolutions received over two-thirds of the votes from participating shareholders [6] Legal Confirmation - The meeting was witnessed by Beijing Hairun Tianrui Law Firm, confirming that the meeting's procedures complied with legal requirements [6]

Core Insights - The animal health sector experienced a rise of 2.65% on November 13, with BioShares leading the gains [1] - The Shanghai Composite Index closed at 4029.5, up 0.73%, while the Shenzhen Component Index closed at 13476.52, up 1.78% [1] Stock Performance - BioShares (600201) closed at 11.74, with a significant increase of 9.11% and a trading volume of 1.153 million shares, amounting to a turnover of 1.3 billion yuan [1] - Other notable performers included *ST Green Health (002868) with a 5.00% increase, and Haili Biological (603718) with a 1.72% increase [1] - The overall trading volume and turnover for the animal health sector showed varied performance among individual stocks [1][2] Capital Flow - The animal health sector saw a net outflow of 32.7945 million yuan from institutional investors, while retail investors contributed a net inflow of 22.6275 million yuan [2][3] - The capital flow analysis indicates that while institutional investors withdrew funds, retail investors were more active in purchasing shares [2][3] Individual Stock Capital Flow - BioShares (600201) had a net inflow of 26.5431 million yuan from institutional investors, while retail investors showed a net outflow of 51.2945 million yuan [3] - *ST Green Health (002868) experienced a net inflow of 6.8361 million yuan from institutional investors, but a net outflow from retail investors [3] - The capital flow data highlights the contrasting behaviors of different investor types within the sector [3]